Interferon gene stimulator composition comprising indolizine derivative as active ingredient
AssigneesAjou University Industry-Academic Cooperation Foundation, Korea Institute of Science and Technology
InventorsEunha Kim, Sanghee Lee, Sang-Kee Choi, Hyungi Kim, Hee Ra Jung
Life of this patent
Estimating the term…
Abstract
The present invention relates to an interferon gene stimulator composition containing an indolizine derivative as an active ingredient. The composition may overcome the problem of low disease control rate, unlike the use of a cyclic-di-nucleotide alone. Specifically, since the composition contains the cyclic-di-nucleotide together with the compound of Formula 1, it may exhibit high activity even when a low concentration of the cyclic-di-nucleotide is used.
Claims7
A method for stimulating interferon gene comprising administering an effective amount of an indolizine derivative compound represented by the following Formula 1;
- and a cyclic-di-nucleotide:
- wherein
- R1 is hydrogen, a C1-C8 straight or branched chain alkyl group, a halogen-substituted C1-C8 straight or branched chain alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a halogen group, a nitrile group, a hydroxyl group, a C1-C6 alkoxy group, —COY1 (wherein Y1 is hydrogen, a C1-C8 straight or branched chain alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C20 aryl group), —CO2Y2 (wherein Y2 is hydrogen, a C1-C8 straight or branched chain alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C20 aryl group), or —NY3Y4 (wherein Y3 and Y4 are each independently hydrogen, a C1-C10 alkyl group, a C6-C20 aryl group, or a C4-C20 heteroaryl group);
- R2 is
- or a pyridinyl group, wherein
- R4 and R5 are each independently hydrogen, a C1-C8 straight or branched chain alkyl group, a halogen-substituted C1-C8 straight or branched chain alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, a C5-C20 heterocycloalkyl group, a C6-C20 aryl group, a C6-C20 heteroaryl group, a halogen group, a nitrile group, a nitro group, a hydroxyl group, a carboxyl group, a C1-C6 alkoxy group, —COY5 (wherein Y5 is hydrogen, a C1-C8 straight or branched chain alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C20 aryl group), —CO2Y6 (wherein Y6 is hydrogen, a C1-C8 straight or branched chain alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, a C6-C20 aryl group), or —NY7Y8 (wherein Y7 and Y5 are each independently hydrogen, a C1-C10 alkyl group, a C6-C20 aryl group, or a C4-C20 heteroaryl group);
- and
- R3 is a C1-C8 straight or branched chain alkyl group, or
- wherein
- R6 is hydrogen, a C1-C8 straight or branched chain alkyl group, a halogen-substituted C1-C8 straight or branched chain alkyl group, a C2-C8 alkenyl group, a C2-C5 alkynyl group, a C3-C8 cycloalkyl group, a C5-C20 heterocycloalkyl group, a C6-C20 aryl group, a C6-C20 heteroaryl group, a halogen group, a nitrile group, a nitro group, a hydroxyl group, a C1-C6 alkoxy group, —COY9 (wherein Y9 is hydrogen, a C1-C8 straight or branched chain alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C20 aryl group), —CO2Y10 (wherein Y10 is hydrogen, a C1-C8 straight or branched chain alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C20 aryl group), or —NY11Y12 (wherein Y11 and Y12 are each independently hydrogen, a C1-C10 alkyl group, a C6-C20 aryl group, or a C4-C20 heteroaryl group),
- wherein the cyclic-di-nucleotide is any one of the following compounds:
Dependencies are inferred from the claim text.